New research reveals a statistical technique used in Alzheimer's drug trials inflates clinical efficacy claims by 29x.

A statistical approach being used to support a new class of Alzheimer's drugs may lead to overstated claims about how the ...

Scientists have reversed Alzheimer’s-like symptoms in mice using specially engineered nanoparticles. The treatment restored ...

The FDA has approved AstraZeneca's aldosterone synthase inhibitor (ASI) – baxdrostat – for hard-to-treat hypertension, making ...

Biogen (NasdaqGS:BIIB) has completed its acquisition of Apellis Pharmaceuticals, adding marketed drugs in complement-driven diseases and nephrology to its portfolio. The company has moved its first-in ...

Sanofi (ENXTPA:SAN) is expanding its global Artificial Intelligence Centre of Excellence in Toronto, deepening its focus on AI applications across drug development and manufacturing. The company is ...

For decades, ultrasound has been associated with diagnostics – a routine scan in a hospital room, a monitor displaying organs ...

Continued progress towards initiating planned Phase 3 trial evaluating neflamapimod in patients with dementia with Lewy bodies in second half of 2026, subject to financing ...

Vietnam Veterans of America Chapter 1145 Aiken will meet at 6:30 p.m. on Tuesday, May 19. The meeting will be held at ...

Last Patient Evaluation Visit Completed with Topline Data Release Targeted Q3-2026 CARSON CITY, Nev., May 18, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie” or the "Company”), a ...

BioVie Inc. (NASDAQ: BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative ...